Spots Global Cancer Trial Database for adenocarcinoma, pancreatic
Every month we try and update this database with for adenocarcinoma, pancreatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) |